AbCellera Biologics Inc. (ABCL) SEC filings

ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30155% above fair value

$11.49−0.13 (-1.12%)

Close on Nov 13, 2026Market cap $3.52BP/E –Yield –

SEC filings

40 of AbCellera Biologics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Nov 9, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 10, 2026	Aug 10, 2026	SEC EDGAR
Current report	8-K	Aug 7, 2026	Aug 7, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jul 29, 2026	Jul 29, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jul 6, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 17, 2026	SEC EDGAR
Current report	8-K	Jun 11, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	Jun 1, 2026	Jun 5, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 11, 2026	SEC EDGAR
Current report	8-K	May 11, 2026	May 11, 2026	SEC EDGAR
Proxy statement	DEF 14A	Dec 31, 2025	Apr 29, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 24, 2026	SEC EDGAR
Current report	8-K	Feb 24, 2026	Feb 24, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 14, 2026	SEC EDGAR
Current report	8-K	Dec 18, 2025	Dec 18, 2025	SEC EDGAR
Current report	8-K	Nov 24, 2025	Nov 28, 2025	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 12, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Sep 10, 2025	Sep 10, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 12, 2025	Jun 13, 2025	SEC EDGAR
Current report	8-K	May 30, 2025	May 30, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 12, 2025	May 13, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 31, 2024	Apr 29, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 27, 2025	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 18, 2025	Feb 18, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 4, 2024	SEC EDGAR
Current report	8-K	Nov 4, 2024	Nov 4, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Aug 6, 2024	Aug 6, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in AbCellera Biologics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ABCL.

Compare: ABCL vs BCYC · ABCL vs ASMB · ABCL vs ENTA · ABCL vs WVE · ABCL vs RXRX

Revenue growth92.1% · median 80.2%

Operating margin-298.0% · median -189.4%

Net margin-218.5% · median -169.8%

Company	Revenue	Growth
BCYC	$83.53M	+194.7%
WVE	$70.92M	–
RXRX	$68.23M	+56.2%
ABCL	$67.86M	+92.1%
ASMB	$67.01M	+80.2%
ENTA	$65.26M	–

Company

Next earnings (est.): Feb 23, 2027, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 562
Held by institutions: 37.9%
Auditor: KPMG LLPChartered Professional Accountants
SEC CIK: 1703057

Advertisement
300 × 250

See a number that looks wrong?